Pancreatic Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

 Breaking News
  • No posts were found

Pancreatic Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

October 10
21:59 2023
Pancreatic Cancer Pipeline, Clinical Trials Studies, Agreements & Collaborations, and Latest News 2023 (Updated)

DelveInsight’s, “Pancreatic Cancer Pipeline Insight 2023” report provides comprehensive insights about 290+ companies and 300+ pipeline drugs in the Pancreatic Cancer pipeline landscape. It covers the Pancreatic Cancer pipeline drug profiles, including clinical and nonclinical stage products. It also covers the Pancreatic Cancer pipeline therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Key Takeaways from the Pancreatic Cancer Pipeline Report

  • DelveInsight’s Pancreatic Cancer pipeline report depicts a robust space with 290+ active players working to develop 300+ pipeline therapies for Pancreatic Cancer treatment.
  • The leading companies working in the Pancreatic Cancer Market include ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
  • Promising Pancreatic Cancer Pipeline Therapies in the various stages of development include Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.
  • September 2023: Golden Biotechnology Corporation announced a study of Phase 1 & 2 Clinical trials for Antroquinonol. The proposed clinical trial is a Phase I/II study designed to evaluate antroquinonol in combination with nab-paclitaxel and gemcitabine in first line treatment naïve subjects with Stage IV metastatic pancreatic carcinoma. The first part of study will focus on the treatment of pancreatic cancer with 200 mg TID and 300 mg TID, clinical treatment duration of 4 weeks, to determine the MTD or MFD (based on PK and capsules strength) of antroquinonol in combination with a standard dose regimen of nab-paclitaxel and gemcitabine.
  • October 2023: Helix BioPharma Corporation announced a study of Phase 1 & 2 clinical trials for L-DOS47 and Doxorubicin. This study will evaluate the safety and tolerability of escalating doses of L-DOS47 in combination with doxorubicin, as well as preliminary anti-tumor activity in patients with previously treated advanced pancreatic cancer.

 

Request a sample and discover the recent advances in Pancreatic Cancer Treatment Drugs @ Pancreatic Cancer Pipeline Report

 

In the Pancreatic Cancer pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Pancreatic Cancer collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Pancreatic Cancer Overview

Pancreatic cancer is a disease in which malignant or cancer cells form in the tissues of the pancreas. Pancreatic cancer begins in the tissues of the pancreas – an organ in the abdomen that lies behind the lower part of the stomach. Pancreatic cancer most frequently arises from pancreatic intraepithelial neoplasia (PanIN), the classic pre-neoplastic lesions, but can also arise from larger precursor lesions, namely, intraductal papillary mucinous neoplasms (IPMNs) and mucinous cystic neoplasms. It exhibits aberrant autocrine and paracrine signalling cascades that promote pancreatic cancer cell proliferation, migration, invasion, and metastasis.

 

Find out more about Pancreatic Cancer Therapeutics Assessment @ Pancreatic Cancer Preclinical and Discovery Stage Products

 

Pancreatic Cancer Emerging Drugs Profile

  • NIS793: Novartis AG
  • Devimistat: Cornerstone Pharmaceuticals
  • Masitinib: AB Science
  • SBP-101: Panbela Therapeutics
  • TAS-102: Taiho Pharmaceutical Co., Ltd.
  • RAIN-32: Rain Oncology
  • IMX-110: Immix Biopharma

 

Pancreatic Cancer Pipeline Therapeutics Assessment

There are approx. 290+ key companies which are developing the Pancreatic Cancer therapies. The Pancreatic Cancer companies which have their Pancreatic Cancer drug candidates in the most advanced stage, i.e. phase III include, Novartis.

 

Learn more about the emerging Pancreatic Cancer Pipeline Therapies @ Pancreatic Cancer Clinical Trials Assessment

 

Scope of the Pancreatic Cancer Pipeline Report

  • Coverage- Global
  • Pancreatic Cancer Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
  • Pancreatic Cancer Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
  • Pancreatic Cancer Companies- ERYtech Pharma, Jiangsu HengRui Medicine Co., Ltd., FibroGen, Novartis AG, AB Science, Eleison Pharmaceuticals, Cornerstone Pharmaceuticals, Panbela Therapeutics, Taiho Pharmaceutical Co., Ltd., Rain Oncology, Redx Pharma Plc, Eli Lilly and Company, Jazz Pharmaceuticals, Immodulon Therapeutics Ltd, GSK, Merck Sharp & Dohme LLC, Roche, Helsinn Healthcare SA, DEKA Biosciences, Senhwa Biosciences, Cue Biopharma, Carisma Therapeutics Inc., ChemoCentryx, Boehringer Ingelheim, Bicara Therapeutics, Arcus Biosciences, Mainline Biosciences, Beijing Imunopharm Technology Co., Ltd., TriSalus Life Sciences, Ono Pharmaceutical, Exelixis, Wellmaker Bio, Pionyr Immunotherapeutics, Ability Pharmaceuticals SL, A2 Biotherapeutics, Klus Pharma Inc., Nelum Corp, Crystal Genomics Inc., Elicio Therapeutics, Turning Point Therapeutics, Immuneering Corporation, pHion Therapeutics Ltd., AC BioScience, TheraVectys, Opna Bio, Cytuvax, Eureka Therapeutics, and others.
  • Pancreatic Cancer Pipeline Therapies- Gemcitabine plus TS-1, Gemcitabine, FOLFOX, Nanoplatin (NC-6004) and Gemcitabine, and others.

 

Dive deep into rich insights for new drugs for Pancreatic Cancer Treatment, Visit @ Pancreatic Cancer Market Drivers and Barriers, and Future Perspective

 

Table of Content

  1. Introduction
  2. Executive Summary
  3. Pancreatic Cancer: Overview
  4. Pipeline Therapeutics
  5. Therapeutic Assessment
  6. Pancreatic Cancer – DelveInsight’s Analytical Perspective
  7. Late Stage Products (Phase III)
  8. Pamrevlumab: FibroGen
  9. Drug profiles in the detailed report…..
  10. Mid Stage Products (Phase II)
  11. Niraparib: Innovent Biologics
  12. Drug profiles in the detailed report…..
  13. Early Stage Products (Phase I/II)
  14. CT041: CARsgen Therapeutics
  15. Drug profiles in the detailed report…..
  16. Preclinical and Discovery Stage Products
  17. ONC 212: Oncoceutics
  18. Drug profiles in the detailed report…..
  19. Inactive Products
  20. Pancreatic Cancer Key Companies
  21. Pancreatic Cancer Key Products
  22. Pancreatic Cancer- Unmet Needs
  23. Pancreatic Cancer- Market Drivers and Barriers
  24. Pancreatic Cancer- Future Perspectives and Conclusion
  25. Pancreatic Cancer Analyst Views
  26. Pancreatic Cancer Key Companies
  27. Appendix

 

For further information on the Pancreatic Cancer Pipeline therapeutics, reach out to Pancreatic Cancer Unmet Needs and Analyst Views

 

About Us

DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/consulting/ci-tracking

Related Articles

Categories